Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

47.78 +1.05 (+2.25%)
Streaming Delayed Price Updated: 1:14 PM EDT, Jul 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
36 37 Next >
News headline image
What's Going On With Crispr Therapeutics Stock Monday? ↗
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Monday on what appears to be continued momentum from the recent regulatory authorization of the company's  
Via Benzinga
News headline image
Google’s Bard AI Says These 3 Stocks Will Rise 1,000% ↗
Google's Bard has been among the best stock pickers, and thinks these three stocks have quadruple-digit upside potential. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street ↗
Investment bank analysts are pounding the table on these stocks, but are they right for your portfolio? 
Via The Motley Fool
News headline image
Could Investing $10,000 In CRISPR Therapeutics Stock Make You a Millionaire? ↗
The stock is trading below its peak, reached a couple of years ago. 
Via The Motley Fool
News headline image
3 Monster Stocks in the Making ↗
These stocks could grow much larger over the next few years. 
Via The Motley Fool
News headline image
Why CRISPR Therapeutics Stock Is Jumping Again Today ↗
The stock continues to enjoy momentum from a key regulatory approval. 
Via The Motley Fool
News headline image
Ross Stores Reports Strong Earnings, Joins Buckle, Twist Bioscience And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded mostly lower, with the Dow Jones falling over 20 points on Friday. 
Via Benzinga
Topics Stocks
News headline image
CRISPR Therapeutics Stock Earns 88 RS Rating On U.K. Regulator News ↗
CRISPR Therapeutics sees its Relative Strength Rating enter the 80-plus level. 
Via Investor's Business Daily
News headline image
3 Long-Term Growth Stocks Analysts Are Bullish On ↗
Here are three long-term growth stocks for your consideration if you’re looking to take a long position in a new name or two. 
Via InvestorPlace
News headline image
3 Cathie Wood You’ll Regret Not Buying Soon: November 2023 ↗
Cathie Wood thinks we're out of the woods economically, and these stock picks in her portfolio stand to gain the most in coming months. 
Via InvestorPlace
News headline image
Why Is NIO Stock Down 5% Today? ↗
Nio stock is falling on Thursday as investors react to negative news following the summit between Presidents Xi Jinping and Joe Biden. 
Via InvestorPlace
News headline image
Crispr Surges After Winning The First-Ever Approval For A CRISPR-Based Gene-Editing Drug ↗
The drug will sell under the brand name Casgevy in the UK for two blood diseases. 
Via Investor's Business Daily
News headline image
What's Going On With Crispr Therapeutics Stock Thursday? ↗
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Thursday after the company announced regulatory authorization of the first CRISPR/Cas9 gene- 
Via Benzinga
News headline image
Citi Is Souring on Plug Power (PLUG) Stock ↗
Plug Power stock is falling on Thursday after the EV charging company's shares were hit with a downgrade and lowered price target from Citi. 
Via InvestorPlace
News headline image
CRISPR Therapeutics (CRSP) Stock Jumps as U.K. Authorizes Gene Therapy ↗
CRSP stock is up on U.K. authorization for its gene therapy treatment for sickle cell anemia. CRISPR hopes for FDA authorization next spring. 
Via InvestorPlace
News headline image
UK Approves First Crispr Gene Edited Therapy For Sickle Cell Disease, Beta Thalassemia ↗
The U.K. 
Via Benzinga
News headline image
Why Palo Alto Networks Shares Are Trading Lower By Around 5%; Here Are 20 Stocks Moving Premarket ↗
Shares of Palo Alto Networks, Inc. (NASDAQ: PANW) fell in pre-market trading after reporting first-quarter results. 
Via Benzinga
News headline image
Can CRISPR Therapeutics Stock Double in 5 Years? Here's What It Would Take. ↗
A few things put together could push the stock higher. 
Via The Motley Fool
News headline image
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Invest in the Future With These 7 Forever Stocks ↗
Forever stocks are usually those predicting future trends. Finding them today means pinning down strong financials and prospects without FOMO. 
Via InvestorPlace
News headline image
3 Biotech Stocks With Key Catalysts Coming in December ↗
Some of the most exciting opportunities can be found in biotech stocks, especially if there's a powerful catalyst just around the corner. 
Via InvestorPlace
News headline image
2 Stocks to Buy Hand Over Fist as the S&P 500 Rockets Higher ↗
These stocks look reasonably priced today considering their long-term prospects. 
Via The Motley Fool
Topics Stocks
News headline image
What's Going On With CRISPR Therapeutics Stock? ↗
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Monday after Morgan Stanley maintained the company with an Underweight rating and lowered the price target. What To Know: 
Via Benzinga
News headline image
3 Biotech Stocks That Are Poised to Have Breakthroughs in 2024 ↗
Investors should consider these "Goldilocks" biotech stocks to buy as they are poised to get significant boosts next year. 
Via InvestorPlace
News headline image
1 No-Brainer Stock to Buy and Hold for 10 Years ↗
This company has been in the news for much of the year. 
Via The Motley Fool
News headline image
3 Growth Stocks to Buy Right Now Without Any Hesitation ↗
Investors shouldn't have to deliberate for too long about these great stocks. 
Via The Motley Fool
News headline image
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review ↗
The major indexes ended long win streaks. Datadog led earnings winners. 
Via Investor's Business Daily
News headline image
3 Biotech Stocks That Are Betting on the Future of Gene Editing ↗
These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now. 
Via InvestorPlace
News headline image
This Program for a Common Problem May Be Vertex Pharmaceuticals' Ticket to a New Wave of Billion-Dollar Revenues ↗
Vertex shares look cheap today considering all the company has to offer. 
Via The Motley Fool
News headline image
3 Biotech Stocks With the Strongest Clinical Pipelines ↗
Many industry heavyweights are on the hunt for fresh new ideas -- great news for biotech stocks to buy with strong pipelines. 
Via InvestorPlace
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.